BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HemoCue Defends Its Hemoglobin Patent Against EKF diagnostic GmbH And Stanbio Laboratory


12/12/2005 12:23:10 PM

LAKE FOREST, Calif., Dec. 12 /PRNewswire/ -- HemoCue AB, a privately held Swedish manufacturer of medical diagnostic systems and HemoCue, Inc. announce that, as part of their effort to enforce their hemoglobin cuvette patent against German manufacturer EKF diagnostic GmbH and its U.S. distributor, Stanbio Laboratory, L.P., the patent is currently being reexamined by the U.S. Patent Office. The HemoCue companies are confident of a favorable outcome for their reexamination and enforcement efforts.

HemoCue is a leader in the development, manufacturing and marketing of advanced medical testing systems that bring lab-quality results to the point-of-care. Its leading products include hemoglobin, glucose, and urine albumin point-of-care testing systems. These products find a wide use in modern health care such as the ER, for assessment of blood loss and in primary care for anemia screening, diagnosis of diabetes and for the early detection of renal and cardiovascular disease. For additional product information, please call +1 800-323-1674 or visit http://www.hemocue.com.

HemoCue AB

CONTACT: Clas Runnberg, Head of Corporate Affairs, +46 431 45 82 70,clas.runnberg@hemocue.se, or Don DuBois, General Manager, +1 949 859 3070,don@hemocue.com, both of HemoCue AB



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES